Literature DB >> 1360798

Effects of medetomidine, an alpha-2 adrenoceptor agonist, and atipamezole, an alpha-2 antagonist, on spatial memory performance in adult and aged rats.

S Carlson1, H Tanila, P Rämä, E Mecke, A Pertovaara.   

Abstract

The effects of a novel, highly selective alpha-2 agonist, medetomidine, and its antagonist, atipamezole, were studied on the working memory of rats performing a spatial delayed alternation task. Testing was performed in two stages, at the age of 8.3 months (mean) and again when the rats were 17.6 months (mean). A low dose (3 micrograms/kg) and a high dose (30 micrograms/kg) of medetomidine improved the performance of the old rats in the memory task but had no effect on the young rats. The dose-response curve of medetomidine resembles that of guanfacine, another alpha-2 agonist. At the low dose of medetomidine (3 micrograms/kg) the animals showed no signs of sedation. Since medetomidine even at a low dose has a beneficial effect on the memory performance of old rats, it could be a good candidate for the treatment of age-associated memory dysfunction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360798     DOI: 10.1016/0163-1047(92)90327-z

Source DB:  PubMed          Journal:  Behav Neural Biol        ISSN: 0163-1047


  18 in total

Review 1.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

2.  Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex.

Authors:  S M Clinton; I L Sucharski; J M Finlay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

3.  Lost in transition: aging-related changes in executive control by the medial prefrontal cortex.

Authors:  Marcelo S Caetano; Nicole K Horst; Linda Harenberg; Benjamine Liu; Amy F T Arnsten; Mark Laubach
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

4.  Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast.

Authors:  Neil Easton; Yasmene B Shah; Fiona H Marshall; Kevin C Fone; Charles A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

5.  Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.

Authors:  Thomas W McAllister; Brenna C McDonald; Laura A Flashman; Richard B Ferrell; Tor D Tosteson; Norman N Yanofsky; Margaret R Grove; Andrew J Saykin
Journal:  Int J Psychophysiol       Date:  2011-07-19       Impact factor: 2.997

6.  Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals.

Authors:  Brian P Ramos; David Stark; Luis Verduzco; Christopher H van Dyck; Amy F T Arnsten
Journal:  Learn Mem       Date:  2006-11-13       Impact factor: 2.460

Review 7.  Adrenergic targets for the treatment of cognitive deficits in schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Psychopharmacology (Berl)       Date:  2003-12-19       Impact factor: 4.530

8.  Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.

Authors:  Jenna S Franowicz; Lynn E Kessler; Catherine M Dailey Borja; Brian K Kobilka; Lee E Limbird; Amy F T Arnsten
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

9.  Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine.

Authors:  Alessandro Gozzi; Stefano Lepore; Elena Vicentini; Emilio Merlo-Pich; Angelo Bifone
Journal:  Neuropsychopharmacology       Date:  2013-05-08       Impact factor: 7.853

10.  Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.

Authors:  Angela Y Gemperle; Kevin H McAllister; Hans-Rudolf Olpe
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.